biologics

Avelumab safety profile is “acceptable”Immunotherapy improves Merkel cell carcinoma, but questions remain.
Guselkumab front and center at EADV Congress
Guselkumab front and center at EADV CongressIL-23 inhibitors represent one more very effective strategy for controlling psoriasis with PASI rates comparable to other biologics.
Oral specialty drug options on the horizonAs more specialty drugs are approved, cost control strategies are key.
Biologic risk tolerance differs for pregnant patientsOf several biologic agents that women of reproductive age can choose from to treat and manage psoriasis, not all have the same safety profile during pregnancy and lactation periods.
July Clinical ConsiderationsIn this month's Clinical Considerations, we take a look at biologics and treatments for seborrheic keratoses.
Prescribing barriersDermatologists who plan to prescribe brodalumab may face a rough road.
FDA approves Bayer’s Bluetooth-enabled auto-injector for multiple sclerosisFDA has approved a supplemental Biologics License Application (sBLA) for Bayer’s myBETAapp and BETACONNECT Navigator for multiple sclerosis (MS) patients
Adverse Reactions Associated with Biologics for Moderate-to-Severe Plaque Psoriasis
Adverse Reactions Associated with Biologics for Moderate-to-Severe Plaque PsoriasisIn July, our table of the month sums up biologics approved for moderate-to-severe plaque psoriasis and common adverse events associated with these biologics.
Biosimilar familiarity expandsDermatologists and some psoriasis patients might soon grapple with switching from a biologic to a biosimilar.
Biologic class differentiatorsDermatology experts offer insight into differentiating factors among TNF-alpha inhibitors, the IL 12/23 antagonist, IL 17 inhibitors and an oral option that carry considerations for managing certain patients.